Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 while oncogenic Ras is a dominant predictor for resistance

Míreanna Comhchosúla

• The PPARγ agonist pioglitazone prevents the hyperglycemia caused by phosphoinositide-3-kinase pathway inhibition by PX-866 without affecting antitumor activity
  le: Ihle, Nathan T., et al.
  Foilsithe: (2009)
• The phosphoinositide-3-kinase inhibitor PX-866 overcomes resistance to the EGFR inhibitor gefitinib in A-549 human non small cell lung cancer xenografts.
  le: Ihle, Nathan T., et al.
  Foilsithe: (2005)
• Inhibitors of phosphatidylinositol-3-kinase in cancer therapy
  le: Ihle, Nathan T., et al.
  Foilsithe: (2010)
• Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma
  le: Koul, Dimpy, et al.
  Foilsithe: (2010)
• Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells
  le: Harder, Bryan G., et al.
  Foilsithe: (2019)